Lilly Endowment Sold $406M in Eli Lilly Stock in Six Weeks — And Still Owns $100B

$406 Million in Sales, $100 Billion Still on the Table

Lilly Endowment Inc., the Indianapolis-based philanthropic foundation and one of the largest charitable organizations in the United States, sold 376,076 shares of Eli Lilly & Co (LLY) worth approximately $406 million between November 21 and December 29, 2025, according to Form 4 filings with the SEC.

The scale is enormous. But context matters: Lilly Endowment still holds 92.2 million shares after these dispositions — a stake worth roughly $100 billion at current prices. The sales represent less than 0.5% of the Endowment’s total LLY position.

The Selling Timeline

Date	Transactions	Shares Sold	Avg Price	Est. Value
Nov 21	8	64,614	$1,063.00	$68.6M
Nov 24	6	142,307	$1,070.96	$152.1M
Nov 25	33	162,693	$1,093.76	$178.4M
Dec 23	1	240	$1,085.04	$0.3M
Dec 24	1	2,629	$1,085.17	$2.9M
Dec 29	1	3,593	$1,085.04	$3.9M
Total	50	376,076	$1,079.64	$406.1M

The heaviest concentration came in a three-day window: November 21–25 accounted for $399 million — 98% of the total. The December sales were comparatively modest at $7.1 million, suggesting the bulk liquidation event was completed before Thanksgiving.

Why Lilly Endowment Sells

Unlike a CEO dumping shares ahead of bad news, Lilly Endowment’s selling follows a well-established institutional pattern. As a private foundation classified as a 10%+ beneficial owner, the Endowment is legally required to distribute approximately 5% of its assets annually for charitable purposes under IRS regulations.

With a portfolio dominated by a single stock — LLY has been the Endowment’s core holding since it was founded by J.K. Lilly Sr. and his sons in 1937 — periodic share sales are the primary mechanism for funding billions of dollars in annual grants to education, community development, and religion-focused programs across Indiana and beyond.

The Endowment’s Form 4 filing history tells this story clearly: $111.8 billion in total sales across 10,747 transactions over the decades. This is not a bearish signal. It is a foundation doing what foundations do.

LLY in Context

Eli Lilly shares traded between $1,063 and $1,110 during the selling window, reflecting the stock’s remarkable run driven by blockbuster demand for GLP-1 drugs Mounjaro and Zepbound. Even after the Endowment’s $406 million in sales, LLY’s daily trading volume easily absorbed the selling pressure without a visible impact on the share price.

The weighted average sale price of ~$1,080 across all transactions suggests the sales were executed systematically through a managed program, not as market orders dumped into the book.

The Numbers in Perspective

• Shares sold: 376,076 (0.41% of Endowment’s total position)
• Value sold: ~$406 million
• Remaining position: 92,190,516 shares (~$100B+ at ~$1,085/share)
• Lifetime Form 4 sales: $111.8 billion across 10,747 transactions
• Price range during sales: $1,063 – $1,110 per share

What to Watch

• Q1 2026 selling: The Endowment’s annual distribution requirements mean selling will continue. Watch for filings in the $100M–$500M range per quarter.
• LLY price sensitivity: At $1,000+ per share, even small share counts generate large dollar-value Form 4 filings. Don’t confuse dollar size with bearish intent.
• Endowment grant announcements: The timing of sales often correlates with major grant cycles. The November concentration may reflect year-end philanthropic commitments.

Track Lilly Endowment’s insider filings and Eli Lilly (LLY) institutional holders on 13F Insight.